Youssef El Khoury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Youssef El Khoury has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Petra Hellwig
Bioelectrochemistry and Spectroscopy Laboratory – University of Strasbourg, UMR 7140, CNRS, Strasbourg 67081, France
14 shared publications - Peter Faller
Institut de Chimie, UMR 7177, Université de Strasbourg, CNRS, 4 Rue Blaise Pascal, 67000 Strasbourg, France
5 shared publications - Ayikoe Guy Mensah-Nyagan
Neuroprotection et Remyélinisation (NeuroRem), Inserm Centre d’Investigation Clinique 1434, Centre de Recherche en Biomédecine de Strasbourg, Université de Strasbourg, 67000 Strasbourg, France
4 shared publications Christine Patte-Mensah
Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, UMR_S1119, Faculty of Medicine, University of Strasbourg, 1, Rue Eugène Boeckel, 67000 Strasbourg, France; Centre d'Investigation Clinique de Strasbourg (CIC), INSERM 1434, bâtiment CRBS, 1, Rue Eugène Boeckel, 67000 Strasbourg, France
4 shared publications- Bertrand Vileno
Institut de Chimie (UMR 7177) University of Strasbourg, CNRS 4 Rue Blaise Pascal 67081 Strasbourg France
3 shared publications - Christian Klein
Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, UMR_S1119, Faculty of Medicine, University of Strasbourg, 1, Rue Eugène Boeckel, 67000 Strasbourg, France; Centre d'Investigation Clinique de Strasbourg (CIC), INSERM 1434, bâtiment CRBS, 1, Rue Eugène Boeckel, 67000 Strasbourg, France
3 shared publications
Latest Publications
- Open Access
- 3 November 2024
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 327, 125390
Assessment of the concomitant action of XBD173 and interferon β in a mouse model of multiple sclerosis using infrared marker bands
- 3 November 2024
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 327, 125390
Open AccessAssessment of the concomitant action of XBD173 and interferon β in a mouse model of multiple sclerosis using infrared marker bands
- Open Access
- 1 August 2024
- Published by Elsevier in SSRN Electronic Journal
Assessment of the Concomitant Action of Xbd173 and Interferon Β in a Mouse Model of Multiple Sclerosis Using Infrared Marker Bands
Disease modifying therapies including interferon-β (IFNβ) effectively counteract the inflammatory component in relapsing-remitting multiple sclerosis (RRMS) but this action, generally associated with severe side effects, does not prevent axonal/neuronal damages. Hence, axonal neuroprotection, which is pivotal for MS effective treatment, remains a difficult clinical challenge. Growing evidence suggested as promising candidate for neuroprotection, Emapunil (AC-5216) or XBD173, a ligand of the mitochondrial translocator protein highly expressed in glial cells and neurons. Indeed, elegant studies previously showed that low and well tolerated doses of XBD173 efficiently improved clinical symptoms and neuropathological markers in MS mice. Here we combined clinical scoring in vivo with Fourier transform infrared spectroscopy of sera samples to investigate the hypothesis that the concomitant treatment of RRMS mice with low doses of IFNβ and XBD173 may increase their beneficial effects against MS symptoms and additionally decrease IFNβ-induced side effects. Our results show a significant alteration of the composition of serum protein and lipids in the spectra of the sera of RRMS mice. While the signature of proteins remains altered upon treatment, the signature of lipids is recovered comparatively well with 20 kIU IFNβ and upon concomitant treatment with a low dose of XBD173 (10 mg/kg) and IFNβ (10 kIU), but not with 10 kIU of IFNβ alone. The concomitant therapy with XBD173 (10 mg/kg) and IFNβ (10 kIU), devoid of side effects, exhibited at least equal or even better efficacy than IFNβ (20 kIU) treatment against RRMS symptoms.
- 1 August 2024
- Published by Elsevier in SSRN Electronic Journal
Open AccessAssessment of the Concomitant Action of Xbd173 and Interferon Β in a Mouse Model of Multiple Sclerosis Using Infrared Marker Bands
Disease modifying therapies including interferon-β (IFNβ) effectively counteract the inflammatory component in relapsing-remitting multiple sclerosis (RRMS) but this action, generally associated with severe side effects, does not prevent axonal/neuronal damages. Hence, axonal neuroprotection, which is pivotal for MS effective treatment, remains a difficult clinical challenge. Growing evidence suggested as promising candidate for neuroprotection, Emapunil (AC-5216) or XBD173, a ligand of the mitochondrial translocator protein highly expressed in glial cells and neurons. Indeed, elegant studies previously showed that low and well tolerated doses of XBD173 efficiently improved clinical symptoms and neuropathological markers in MS mice. Here we combined clinical scoring in vivo with Fourier transform infrared spectroscopy of sera samples to investigate the hypothesis that the concomitant treatment of RRMS mice with low doses of IFNβ and XBD173 may increase their beneficial effects against MS symptoms and additionally decrease IFNβ-induced side effects. Our results show a significant alteration of the composition of serum protein and lipids in the spectra of the sera of RRMS mice. While the signature of proteins remains altered upon treatment, the signature of lipids is recovered comparatively well with 20 kIU IFNβ and upon concomitant treatment with a low dose of XBD173 (10 mg/kg) and IFNβ (10 kIU), but not with 10 kIU of IFNβ alone. The concomitant therapy with XBD173 (10 mg/kg) and IFNβ (10 kIU), devoid of side effects, exhibited at least equal or even better efficacy than IFNβ (20 kIU) treatment against RRMS symptoms.
- Open Access
- 5 August 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (32) , 14758-14768
Copper-Catalyzed Glutathione Oxidation is Accelerated by the Anticancer Thiosemicarbazone Dp44mT and Further Boosted at Lower pH
Glutathione (GSH) is the most abundant thiol in mammalian cells and plays a crucial role in maintaining redox cellular homeostasis. The thiols of two GSH molecules can be oxidized to the disulfide GSSG. The cytosolic GSH/GSSG ratio is very high (>100), and its reduction can lead to apoptosis or necrosis, which are of interest in cancer research. CuII ions are very efficient oxidants of thiols, but with an excess of GSH, CuIn(GS)m clusters are formed, in which CuI is very slowly reoxidized by O2 at pH 7.4 and even more slowly at lower pH. Here, the aerobic oxidation of GSH by CuII was investigated at different pH values in the presence of the anticancer thiosemicarbazone Dp44mT, which accumulates in lysosomes and induces lysosomal membrane permeabilization in a Cu-dependent manner. The results showed that CuII-Dp44mT catalyzes GSH oxidation faster than CuII alone at pH 7.4 and hence accelerates the production of very reactive hydroxyl radicals. Moreover, GSH oxidation and hydroxyl radical production by CuII-Dp44mT were accelerated at the acidic pH found in lysosomes. To decipher this unusually faster thiol oxidation at lower pH, density functional theory (DFT) calculations, electrochemical and spectroscopic studies were performed. The results suggest that the acceleration is due to the protonation of CuII-Dp44mT on the hydrazinic nitrogen, which favors the rate-limiting reduction step without subsequent dissociation of the CuI intermediate. Furthermore, preliminary biological studies in cell culture using the proton pump inhibitor bafilomycin A1 indicated that the lysosomal pH plays a role in the activity of CuII-Dp44mT.
- 5 August 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (32) , 14758-14768
Open AccessCopper-Catalyzed Glutathione Oxidation is Accelerated by the Anticancer Thiosemicarbazone Dp44mT and Further Boosted at Lower pH
Glutathione (GSH) is the most abundant thiol in mammalian cells and plays a crucial role in maintaining redox cellular homeostasis. The thiols of two GSH molecules can be oxidized to the disulfide GSSG. The cytosolic GSH/GSSG ratio is very high (>100), and its reduction can lead to apoptosis or necrosis, which are of interest in cancer research. CuII ions are very efficient oxidants of thiols, but with an excess of GSH, CuIn(GS)m clusters are formed, in which CuI is very slowly reoxidized by O2 at pH 7.4 and even more slowly at lower pH. Here, the aerobic oxidation of GSH by CuII was investigated at different pH values in the presence of the anticancer thiosemicarbazone Dp44mT, which accumulates in lysosomes and induces lysosomal membrane permeabilization in a Cu-dependent manner. The results showed that CuII-Dp44mT catalyzes GSH oxidation faster than CuII alone at pH 7.4 and hence accelerates the production of very reactive hydroxyl radicals. Moreover, GSH oxidation and hydroxyl radical production by CuII-Dp44mT were accelerated at the acidic pH found in lysosomes. To decipher this unusually faster thiol oxidation at lower pH, density functional theory (DFT) calculations, electrochemical and spectroscopic studies were performed. The results suggest that the acceleration is due to the protonation of CuII-Dp44mT on the hydrazinic nitrogen, which favors the rate-limiting reduction step without subsequent dissociation of the CuI intermediate. Furthermore, preliminary biological studies in cell culture using the proton pump inhibitor bafilomycin A1 indicated that the lysosomal pH plays a role in the activity of CuII-Dp44mT.
- Open Access
- 3 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (5) , 2791
Rapid Discrimination of Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Using Machine Learning on Infrared Spectra of Sera
Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) are both autoimmune inflammatory and demyelinating diseases of the central nervous system. NMOSD is a highly disabling disease and rapid introduction of the appropriate treatment at the acute phase is crucial to prevent sequelae. Specific criteria were established in 2015 and provide keys to distinguish NMOSD and MS. One of the most reliable criteria for NMOSD diagnosis is detection in patient’s serum of an antibody that attacks the water channel aquaporin-4 (AQP-4). Another target in NMOSD is myelin oligodendrocyte glycoprotein (MOG), delineating a new spectrum of diseases called MOG-associated diseases. Lastly, patients with NMOSD can be negative for both AQP-4 and MOG antibodies. At disease onset, NMOSD symptoms are very similar to MS symptoms from a clinical and radiological perspective. Thus, at first episode, given the urgency of starting the anti-inflammatory treatment, there is an unmet need to differentiate NMOSD subtypes from MS. Here, we used Fourier transform infrared spectroscopy in combination with a machine learning algorithm with the aim of distinguishing the infrared signatures of sera of a first episode of NMOSD from those of a first episode of relapsing-remitting MS, as well as from those of healthy subjects and patients with chronic inflammatory demyelinating polyneuropathy. Our results showed that NMOSD patients were distinguished from MS patients and healthy subjects with a sensitivity of 100% and a specificity of 100%. We also discuss the distinction between the different NMOSD serostatuses. The coupling of infrared spectroscopy of sera to machine learning is a promising cost-effective, rapid and reliable differential diagnosis tool capable of helping to gain valuable time in patients’ treatment.
- 3 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (5) , 2791
Open AccessRapid Discrimination of Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Using Machine Learning on Infrared Spectra of Sera
Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) are both autoimmune inflammatory and demyelinating diseases of the central nervous system. NMOSD is a highly disabling disease and rapid introduction of the appropriate treatment at the acute phase is crucial to prevent sequelae. Specific criteria were established in 2015 and provide keys to distinguish NMOSD and MS. One of the most reliable criteria for NMOSD diagnosis is detection in patient’s serum of an antibody that attacks the water channel aquaporin-4 (AQP-4). Another target in NMOSD is myelin oligodendrocyte glycoprotein (MOG), delineating a new spectrum of diseases called MOG-associated diseases. Lastly, patients with NMOSD can be negative for both AQP-4 and MOG antibodies. At disease onset, NMOSD symptoms are very similar to MS symptoms from a clinical and radiological perspective. Thus, at first episode, given the urgency of starting the anti-inflammatory treatment, there is an unmet need to differentiate NMOSD subtypes from MS. Here, we used Fourier transform infrared spectroscopy in combination with a machine learning algorithm with the aim of distinguishing the infrared signatures of sera of a first episode of NMOSD from those of a first episode of relapsing-remitting MS, as well as from those of healthy subjects and patients with chronic inflammatory demyelinating polyneuropathy. Our results showed that NMOSD patients were distinguished from MS patients and healthy subjects with a sensitivity of 100% and a specificity of 100%. We also discuss the distinction between the different NMOSD serostatuses. The coupling of infrared spectroscopy of sera to machine learning is a promising cost-effective, rapid and reliable differential diagnosis tool capable of helping to gain valuable time in patients’ treatment.
- 22 July 2021
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 12 (15) , 2940-2945
Raman Imaging Reveals Accumulation of Hemoproteins in Plaques from Alzheimer’s Diseased Tissues
Hemes have been suggested to play a central role in Alzheimer’s disease since they show high peroxidase reactivity when bound to amyloid β peptides, leading to the production of reactive oxygen species. Here we used Fourier transform infrared and Raman imaging on Alzheimer’s diseased mice and human brain tissue. Our finding suggests the accumulation of hemes in the senile plaques of both murine and human samples. We compared the Raman signature of the plaques to the ones of various hemeoproteins and to the hemin-Aβ-42 complex. The detected Raman signature of the plaques does not allow identifying the type of heme accumulating in the plaques.
- 22 July 2021
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 12 (15) , 2940-2945
Raman Imaging Reveals Accumulation of Hemoproteins in Plaques from Alzheimer’s Diseased Tissues
Hemes have been suggested to play a central role in Alzheimer’s disease since they show high peroxidase reactivity when bound to amyloid β peptides, leading to the production of reactive oxygen species. Here we used Fourier transform infrared and Raman imaging on Alzheimer’s diseased mice and human brain tissue. Our finding suggests the accumulation of hemes in the senile plaques of both murine and human samples. We compared the Raman signature of the plaques to the ones of various hemeoproteins and to the hemin-Aβ-42 complex. The detected Raman signature of the plaques does not allow identifying the type of heme accumulating in the plaques.
- Open Access
- 28 March 2021
- Published by AIP Publishing in The Journal of Chemical Physics
- Vol. 154 (12) , 124201
Lessons from combined experimental and theoretical examination of the FTIR and 2D-IR spectroelectrochemistry of the amide I region of cytochrome c
Amide I difference spectroscopy is widely used to investigate protein function and structure changes. In this article, we show that the common approach of assigning features in amide I difference signals to distinct secondary structure elements in many cases may not be justified. Evidence comes from Fourier transform infrared (FTIR) and 2D-IR spectroelectrochemistry of the protein cytochrome c in the amide I range, in combination with computational spectroscopy based on molecular dynamics (MD) simulations. This combination reveals that each secondary structure unit, such as an alpha-helix or a beta-sheet, exhibits broad overlapping contributions, usually spanning a large part of the amide I region, which in the case of difference absorption experiments (such as in FTIR spectroelectrochemistry) may lead to intensity-compensating and even sign-changing contributions. We use cytochrome c as the test case, as this small electron-transferring redox-active protein contains different kinds of secondary structure units. Upon switching its redox-state, the protein exhibits a different charge distribution while largely retaining its structural scaffold. Our theoretical analysis suggests that the change in charge distribution contributes to the spectral changes and that structural changes are small. However, in order to confidently interpret FTIR amide I difference signals in cytochrome c and proteins in general, MD simulations in combination with additional experimental approaches such as isotope labeling, the insertion of infrared labels to selectively probe local structural elements will be required. In case these data are not available, a critical assessment of previous interpretations of protein amide I 1D- and 2D-IR difference spectroscopy data is warranted.
- 28 March 2021
- Published by AIP Publishing in The Journal of Chemical Physics
- Vol. 154 (12) , 124201
Open AccessLessons from combined experimental and theoretical examination of the FTIR and 2D-IR spectroelectrochemistry of the amide I region of cytochrome c
Amide I difference spectroscopy is widely used to investigate protein function and structure changes. In this article, we show that the common approach of assigning features in amide I difference signals to distinct secondary structure elements in many cases may not be justified. Evidence comes from Fourier transform infrared (FTIR) and 2D-IR spectroelectrochemistry of the protein cytochrome c in the amide I range, in combination with computational spectroscopy based on molecular dynamics (MD) simulations. This combination reveals that each secondary structure unit, such as an alpha-helix or a beta-sheet, exhibits broad overlapping contributions, usually spanning a large part of the amide I region, which in the case of difference absorption experiments (such as in FTIR spectroelectrochemistry) may lead to intensity-compensating and even sign-changing contributions. We use cytochrome c as the test case, as this small electron-transferring redox-active protein contains different kinds of secondary structure units. Upon switching its redox-state, the protein exhibits a different charge distribution while largely retaining its structural scaffold. Our theoretical analysis suggests that the change in charge distribution contributes to the spectral changes and that structural changes are small. However, in order to confidently interpret FTIR amide I difference signals in cytochrome c and proteins in general, MD simulations in combination with additional experimental approaches such as isotope labeling, the insertion of infrared labels to selectively probe local structural elements will be required. In case these data are not available, a critical assessment of previous interpretations of protein amide I 1D- and 2D-IR difference spectroscopy data is warranted.
- Open Access
- 6 August 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (44)
Frontispiece: Aggregation and Amyloidogenicity of the Nuclear Coactivator Binding Domain of CREB‐Binding Protein
- 6 August 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (44)
Open AccessFrontispiece: Aggregation and Amyloidogenicity of the Nuclear Coactivator Binding Domain of CREB‐Binding Protein
- 4 May 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (44) , 9889-9899
Aggregation and Amyloidogenicity of the Nuclear Coactivator Binding Domain of CREB‐Binding Protein
The nuclear coactivator binding domain (NCBD) of transcriptional co‐regulator CREB‐binding protein (CBP) is an example of conformationally malleable proteins that can bind to structurally unrelated protein targets and adopt distinct folds in the respective protein complexes. Here, we show that the folding landscape of NCBD contains an alternative pathway that results in protein aggregation and self‐assembly into amyloid fibers. The initial steps of such protein misfolding are driven by intermolecular interactions of its N‐terminal α‐helix bringing multiple NCBD molecules into contact. These oligomers then undergo slow but progressive interconversion into β‐sheet‐containing aggregates. To reveal the concealed aggregation potential of NCBD we used a chemically synthesized mirror‐image d‐NCBD form. The addition of d‐NCBD promoted self‐assembly into amyloid precipitates presumably due to formation of thermodynamically more stable racemic β‐sheet structures. The unexpected aggregation of NCBD needs to be taken into consideration given the multitude of protein–protein interactions and resulting biological functions mediated by CBP.
- 4 May 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (44) , 9889-9899
Aggregation and Amyloidogenicity of the Nuclear Coactivator Binding Domain of CREB‐Binding Protein
The nuclear coactivator binding domain (NCBD) of transcriptional co‐regulator CREB‐binding protein (CBP) is an example of conformationally malleable proteins that can bind to structurally unrelated protein targets and adopt distinct folds in the respective protein complexes. Here, we show that the folding landscape of NCBD contains an alternative pathway that results in protein aggregation and self‐assembly into amyloid fibers. The initial steps of such protein misfolding are driven by intermolecular interactions of its N‐terminal α‐helix bringing multiple NCBD molecules into contact. These oligomers then undergo slow but progressive interconversion into β‐sheet‐containing aggregates. To reveal the concealed aggregation potential of NCBD we used a chemically synthesized mirror‐image d‐NCBD form. The addition of d‐NCBD promoted self‐assembly into amyloid precipitates presumably due to formation of thermodynamically more stable racemic β‐sheet structures. The unexpected aggregation of NCBD needs to be taken into consideration given the multitude of protein–protein interactions and resulting biological functions mediated by CBP.
- 5 December 2019
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (8) , 1871-1879
Acrolein and Copper as Competitive Effectors of α‐Synuclein
Mounting evidence supports the role of amyloidogenesis, oxidative stress, and metal dyshomeostasis in the development of neurodegenerative disorders. Parkinson's Disease is characterized by α‐synuclein (αSyn) accumulation and aggregation in brain regions, also promoted by Cu2+. αSyn is modified by reactive carbonyl species, including acrolein (ACR). Notwithstanding these findings, the interplay between ACR, copper, and αSyn has never been investigated. Therefore, we explored more thoroughly the effects of ACR on αSyn using an approach based on LC‐MS/MS analysis. We also evaluated the influence of Cu2+ on the protein carbonylation and how the ACR modification impacts the Cu2+ binding and the production of Reactive Oxygen Species (ROS). Finally, we investigated the effects of ACR and Cu2+ ions on the αSyn aggregation by dynamic light scattering and fluorescence assays. Cu2+ regioselectively inhibits the modification of His50 by ACR, the carbonylation lowers the affinity of His50 for Cu2+ and ACR inhibits αSyn aggregation both in the presence and in the absence of Cu2+.
- 5 December 2019
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (8) , 1871-1879
Acrolein and Copper as Competitive Effectors of α‐Synuclein
Mounting evidence supports the role of amyloidogenesis, oxidative stress, and metal dyshomeostasis in the development of neurodegenerative disorders. Parkinson's Disease is characterized by α‐synuclein (αSyn) accumulation and aggregation in brain regions, also promoted by Cu2+. αSyn is modified by reactive carbonyl species, including acrolein (ACR). Notwithstanding these findings, the interplay between ACR, copper, and αSyn has never been investigated. Therefore, we explored more thoroughly the effects of ACR on αSyn using an approach based on LC‐MS/MS analysis. We also evaluated the influence of Cu2+ on the protein carbonylation and how the ACR modification impacts the Cu2+ binding and the production of Reactive Oxygen Species (ROS). Finally, we investigated the effects of ACR and Cu2+ ions on the αSyn aggregation by dynamic light scattering and fluorescence assays. Cu2+ regioselectively inhibits the modification of His50 by ACR, the carbonylation lowers the affinity of His50 for Cu2+ and ACR inhibits αSyn aggregation both in the presence and in the absence of Cu2+.
- Open Access
- 13 June 2019
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 55 (56) , 8110-8113
Triggering Cu-coordination change in Cu( ii )-Ala-His-His by external ligands
A switch in copper( ii )-coordination between the two motifs Xxx-Zzz-His (ATCUN) and Xxx-His in the hybride peptide Ala-His-His is induced by adding a ligand such as imidazole.
- 13 June 2019
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 55 (56) , 8110-8113
Open AccessTriggering Cu-coordination change in Cu( ii )-Ala-His-His by external ligands
A switch in copper( ii )-coordination between the two motifs Xxx-Zzz-His (ATCUN) and Xxx-His in the hybride peptide Ala-His-His is induced by adding a ligand such as imidazole.